Welcome to our dedicated page for GridAI Technologies SEC filings (Ticker: ENTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GridAI Technologies's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GridAI Technologies's regulatory disclosures and financial reporting.
GridAI Technologies Corp. received a Schedule 13G/A filing from Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reporting a passive ownership position. The reporting persons beneficially own 31,000 shares of common stock, representing 0.92% of the class as of 12/31/2025.
Renaissance reports sole voting and dispositive power over these shares and confirms they are held in the ordinary course of business, not for the purpose of changing or influencing control of GridAI. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds from these securities.
GridAI Technologies Corp. received a new Schedule 13G disclosure showing that Strategic EP, LLC and Alexander Chase Deitch together report beneficial ownership of 209,541 shares of common stock, representing 5.0% of the company’s outstanding shares. This percentage is based on 4,162,695 shares outstanding as of the date of the statement. The filing states the investors share voting and dispositive power over these shares and classify themselves as passive holders, certifying that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control. They also hold warrants and pre-funded warrants subject to 4.99% or 9.99% beneficial ownership limits, so the underlying shares are excluded from the reported ownership.
GridAI Technologies Corp. director Edward Borkowski reported a stock grant. On January 1, 2026, he was awarded 40,000 restricted stock units that will be settled in shares of common stock with a par value of $0.0001 per share. The filing states these restricted stock units vested immediately upon issuance on January 1, 2026. Following this grant, Borkowski beneficially owns 60,248 shares of common stock directly.
GridAI Technologies Corp. completed a previously agreed rescission transaction involving ImmunogenX, LLC on December 31, 2025. Under this deal, the company transferred to the former ImmunogenX, Inc. shareholders all of the membership interests of ImmunogenX, LLC that it held, so ImmunogenX, LLC is no longer a subsidiary and the company no longer owns any interest in it.
The company notes that this disposition is considered a significant asset sale for reporting purposes, and it has filed unaudited pro forma consolidated financial statements as an exhibit to show how the transaction would have affected its historical financials.
Entero Therapeutics, Inc. reported a Q3 2025 net loss of $1,152,809, improving from $2,580,971 a year earlier as operating expenses declined. For the first nine months of 2025, net loss narrowed to $3,410,700 from $5,821,067 in the prior-year period. Cash and cash equivalents were $2,517,218 at September 30, 2025, with an accumulated deficit of $205,798,707, and management states there is substantial doubt about the company’s ability to continue as a going concern.
Total assets rose to $135,370,340 from $85,409,506, driven by the March 2024 ImmunogenX acquisition and the September 30, 2025 acquisition of Grid AI Corp., which added developed technology, customer relationships, trade name intangibles and $25,796,163 of goodwill. Assets and liabilities related to ImmunogenX, including Latiglutenase and CypCel, are classified as held for sale and treated as discontinued operations. The Grid AI deal also introduced a non-controlling interest of $5,287,000 and new Series H preferred stock that is convertible into common shares subject to shareholder approval.
Entero Therapeutics, Inc. filed a Form 12b-25 to notify that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company is still reviewing the accounting treatment of its acquisition of GridAI Corp. and needs more time to ensure the financial statements comply with applicable accounting standards. Under Rule 12b-25, Entero expects to file the quarterly report no later than the fifth calendar day after the original due date.
Entero Therapeutics (ENTO) reported that on October 17, 2025, the stockholders of GridAI Corp waived their right to appoint two directors to Entero’s Board as provided in Section 5.09 of the Share Exchange Agreement dated September 30, 2025. The waiver remains in effect until Entero’s shareholders approve the appointment of such directors at a duly called meeting in accordance with applicable laws.
This update follows the previously disclosed agreement referenced in the company’s October 6, 2025 filing and reflects a governance step that defers board appointments pending shareholder approval.
Entero Therapeutics (ENTO) reported that Nasdaq has confirmed the company is back in compliance with the minimum stockholders’ equity requirement under Listing Rule 5550(b)(1). Compliance was affirmed in a letter dated October 28, 2025, following Entero’s October 6 disclosure tied to a September 30 share exchange with GridAI.
The company had previously fallen out of compliance after reporting stockholders’ equity of ($3,876,738) as of December 31, 2024, below the $2.5 million minimum. Nasdaq had granted an extension through October 8, 2025, to regain compliance. Nasdaq cautioned that if Entero does not evidence compliance in its next periodic report, the company may face delisting, with the option to appeal to a Hearings Panel.
Entero Therapeutics entered a Securities Purchase Agreement allowing a private placement of up to $5,000,000 in promissory notes and a common stock purchase warrant for up to 1,520,000 shares, with subsequent closings permitted.
At the initial closing on October 17, 2025, the company received $500,000 in gross proceeds by issuing a $500,000 non‑interest‑bearing, non‑convertible Note maturing one year and one day from issuance, which the company may extend in one‑year‑and‑one‑day increments. It also issued a Warrant to purchase up to 200,000 shares at an exercise price of $2.50 per share, exercisable upon stockholder approval and expiring five years after that approval.
The Warrant size may adjust pro rata with additional investments, up to 1,520,000 shares, includes a 4.9% Beneficial Ownership Limitation, and may be exercised cashlessly if the underlying shares are not registered. Entero plans to use proceeds for general corporate purposes, and will seek stockholder approval and file a registration statement for the resale of the Warrant shares.